俄勒冈州 的 非小细胞肺癌 临床试验
俄勒冈州 有 62 项针对 非小细胞肺癌 的研究正在招募参与者。
俄勒冈州 的城市
官方研究文本（英文）
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Providence Cancer Institute Franz Clinic, Portland
- Providence St. Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT07100080A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- St. Charles Health System, Inc ( Site 0146), Bend
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Providence Hood River Memorial Hospital, Hood River
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- 以及另外 3 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Good Samaritan Hospital, Corvallis
- Three Rivers Community Hospital, Grants Pass
- Asante Rogue Regional Medical Center, Medford
- 以及另外 5 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT04267848A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Oregon Health and Science University ( Site 0052), Portland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月10日 · NCT06312137A Study of DS-3939a in Participants With Solid Tumors
- Oregon Health & Science University, Portland
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月10日 · NCT07739966Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Local Institution - 0404, Portland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月10日 · NCT07680790A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217), Corvallis
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月9日 · NCT06623422A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- OHSU Knight Cancer Institute, Beaverton, Beaverton
- Oncology Associates of Oregon, P.C., Eugene
- OHSU Knight Cancer Institute, Gresham, Gresham
- 以及另外 10 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月5日 · NCT07144280A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Oregon Health and Science University, Portland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月5日 · NCT06793215A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Oncology Associates Of Oregon, Pc, Eugene
- Northwest Cancer Specialists, P.C., Happy Valley
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月5日 · NCT07361497Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Providence Portland Medical Center, Portland
- Providence St. Vincent Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT06890598Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT06418204A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Oncology Associates of Oregon, Eugene
- Asante Rogue Regional Medical Center, Medford
- Providence Portland Medical Center, Portland
- 以及另外 2 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT06119581Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- OHSU Knight Cancer Institute, Portland
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月4日 · NCT07397338A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Providence Cancer Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT07586202Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Good Samaritan Hospital, Corvallis
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT03191149A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Providence Cancer Institute, Portland
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT07542704FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Asante Rogue Region al Medical Center, Medford
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT06303505A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Clackamas Radiation Oncology Center, Clackamas
- Providence Newberg Medical Center, Newberg
- Providence Willamette Falls Medical Center, Oregon City
- 以及另外 2 项
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT07293247Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117), Corvallis
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT06170788A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Oregon Health And Science University, Portland
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT06667908Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Williamette Valley Cancer Institute and Research Center, Eugene
- Providence Portland Medical Center, Portland
- Providence Oncology & Hematology Care Clinic - Westside, West Haven-Sylvan
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT07288177Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Providence Cancer Institute, Portland
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月2日 · NCT07195695Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
- Local Institution - 007-885B, Portland
- Local Institution - 007-885A, Portland
- 以及另外 2 项
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月30日 · NCT04613596DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA15-0, Portland
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月29日 · NCT06953089Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Providence Cancer Institute, Portland
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月29日 · NCT05098132A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Medford
- Research Site, Salem
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月29日 · NCT06692738A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月28日 · NCT06242470Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- St. Charles Health System, Bend
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月23日 · NCT06899126A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Oregon Health and Science University, Portland
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月22日 · NCT07154290Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
- OHSU Knight Cancer Institute, Portland
招募中4 期
18 岁及以上 · 所有性别 · 更新于 2026年10月13日 · NCT07405086Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Oregon Health & Science University, Portland
招募中3 期
18 至 100 岁 · 所有性别 · 更新于 2026年10月13日 · NCT05317858Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月9日 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
招募中2 期
18 Minutes · 所有性别 · 更新于 2026年10月9日 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Kaiser Permanente Northwest, Portland
- 以及另外 1 项
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月9日 · NCT06616584Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Northwest Cancer Specialists, P.C, Happy Valley
- Northwest Cancer Specialists, P.C., Portland
- Northwest Cancer Specialists, P.C, Tigard
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月8日 · NCT07222566Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- Oncology Associates of Oregon, P.C., Eugene
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月8日 · NCT07227298The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
招募中1/2 期
12 岁及以上 · 所有性别 · 更新于 2026年10月2日 · NCT04585750数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。